{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:53:14Z","timestamp":1777870394309,"version":"3.51.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40620-019-00690-3","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T06:03:03Z","timestamp":1578549783000},"page":"795-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Changes in the whole\/intact parathyroid hormone ratio and their clinical implications in patients with chronic kidney disease"],"prefix":"10.1093","volume":"33","author":[{"given":"Kohei","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-1068","authenticated-orcid":false,"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"key":"690_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10157-006-0432-9","volume":"10","author":"M Fukagawa","year":"2006","unstructured":"Fukagawa M, Nakanishi S, Fujii H, Hamada Y, Abe T (2006) Regulation of parathyroid function in chronic kidney disease (CKD). Clin Exp Nephrol 10:175\u2013179","journal-title":"Clin Exp Nephrol"},{"key":"690_CR2","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium \u00d7 phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607\u2013617","journal-title":"Am J Kidney Dis"},{"key":"690_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.ackd.2011.02.004","volume":"18","author":"DA Molony","year":"2011","unstructured":"Molony DA, Stephens BW (2011) Derangements in phosphate metabolism in chronic kidney diseases\/endstage renal disease: therapeutic considerations. Adv Chronic Kidney Dis 18:120\u2013131","journal-title":"Adv Chronic Kidney Dis"},{"key":"690_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017) KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1\u201359","journal-title":"Kidney Int Suppl"},{"key":"690_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.4009\/jsdt.45.301","volume":"45","author":"Japanese Society for Dialysis Therapy","year":"2012","unstructured":"Japanese Society for Dialysis Therapy (2012) Guidelines for the management for CKD-MBD. J Jpn Soc Dial Ther 45:301\u2013356 (In Japanese)","journal-title":"J Jpn Soc Dial Ther"},{"key":"690_CR6","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1093\/ndt\/gfm849","volume":"23","author":"ML Melamed","year":"2008","unstructured":"Melamed ML, Eustace JA, Plantinga LC, Jaar BG, Fink NE, Parekh RS, Coresh J, Yang Z, Cantor T, Powe NR (2008) Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transpl 23:1650\u20131658","journal-title":"Nephrol Dial Transpl"},{"key":"690_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/S0085-2538(15)47156-X","volume":"58","author":"E Slatopolsky","year":"2000","unstructured":"Slatopolsky E, Finch J, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A (2000) A novel mechanism for skeletal resistance in uremia. Kidney Int 58:753\u2013761","journal-title":"Kidney Int"},{"key":"690_CR8","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1681\/ASN.2005101136","volume":"17","author":"J Huan","year":"2006","unstructured":"Huan J, Olgaard K, Nielsen LB, Lewin E (2006) Parathyroid hormone 7\u201384 induces hypocalcemia and inhibits the parathyroid hormone 1\u201384 secretory response to hypocalcemia in rats with intact parathyroid glands. J Am Soc Nephrol 17:1923\u20131930","journal-title":"J Am Soc Nephrol"},{"key":"690_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1359\/jbmr.2001.16.4.605","volume":"16","author":"P Gao","year":"2001","unstructured":"Gao P, Scheibel S, D\u02bcAmour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1\u201384: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605\u2013614","journal-title":"J Bone Miner Res"},{"key":"690_CR10","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00198-007-0554-2","volume":"19","author":"M Kurajoh","year":"2008","unstructured":"Kurajoh M, Inaba M, Yamada S, Imanishi Y, Tsuchida T, Ishimura E, Nishizawa Y (2008) Association of increased active PTH(1\u201384) fraction with decreased GFR and serum Ca in predialysis CRF patients: modulation by serum 25-OH-D. Osteoporos Int 19:709\u2013716","journal-title":"Osteoporos Int"},{"key":"690_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.5414\/CNP65328","volume":"65","author":"J Herberth","year":"2006","unstructured":"Herberth J, Fahrleitner-Pammer A, Obermayer-Pietsch B, Krisper P, Holzer H, Malluche HH, Dobnig H (2006) Changes in total parathyroid hormone (PTH), PTH-(1\u201384) and large C-PTH fragments in different stages of chronic kidney disease. Clin Nephrol 65:328\u2013334","journal-title":"Clin Nephrol"},{"key":"690_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/clinchem\/46.5.697","volume":"46","author":"JH Brossard","year":"2000","unstructured":"Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, D\u02bcAmour P (2000) Influence of glomerular filtration rate on non-(1\u201384) parathyroid hormone (PTH) detected by intact PTH assays. Clin Chem 46:697\u2013703","journal-title":"Clin Chem"},{"key":"690_CR13","doi-asserted-by":"publisher","first-page":"c108","DOI":"10.1159\/000089668","volume":"102","author":"T Tsuchida","year":"2006","unstructured":"Tsuchida T, Ishimura E, Hirowatari K, Matsumoto N, Imanishi Y, Jono S, Miki T, Inaba M, Nishizawa Y (2006) Serum levels of 1\u201384 and 7\u201384 parathyroid hormone in predialysis patients with chronic renal failure measured by the intact and bio-PTH assay. Nephron Clin Pract 102:c108\u2013c114","journal-title":"Nephron Clin Pract"},{"key":"690_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2013) KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1\u2013150","journal-title":"Kidney Int Suppl"},{"key":"690_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40620-017-0406-x","volume":"30","author":"S Yamamoto","year":"2017","unstructured":"Yamamoto S, Fukagawa M (2017) Uremic toxicity and bone in CKD. J Nephrol 30:623\u2013627","journal-title":"J Nephrol"},{"key":"690_CR16","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, Guti\u00e9rrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370\u20131378","journal-title":"Kidney Int"},{"key":"690_CR17","doi-asserted-by":"publisher","first-page":"810","DOI":"10.2215\/CJN.08680811","volume":"7","author":"C Nakano","year":"2012","unstructured":"Nakano C, Hamano T, Fujii N, Matsui I, Tomida K, Mikami S, Inoue K, Obi Y, Okada N, Tsubakihara Y, Isaka Y, Rakugi H (2012) Combined use of vitamin D status and FGF23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 7:810\u2013819","journal-title":"Clin J Am Soc Nephrol"},{"key":"690_CR18","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1093\/ndt\/gfg104","volume":"18","author":"JC Estepa","year":"2003","unstructured":"Estepa JC, Lopez I, Felsenfeld AJ, Gao P, Cantor T, Rodriguez M, Aguilera-Tejero E (2003) Dynamics of secretion and metabolism of PTH during hypo- and hypercalcaemia in the dog as determined by the \u2018intact\u2019 and \u2018whole\u2019 PTH assays. Nephrol Dial Transpl 18:1101\u20131107","journal-title":"Nephrol Dial Transpl"},{"key":"690_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1530\/eje.0.1460407","volume":"146","author":"P D\u2019Amour","year":"2002","unstructured":"D\u2019Amour P (2002) Effects of acute and chronic hypercalcemia on parathyroid function and circulating parathyroid hormone molecular forms. Eur J Endocrinol 146:407\u2013410","journal-title":"Eur J Endocrinol"},{"key":"690_CR20","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1007\/s00198-010-1262-x","volume":"22","author":"M Kurajoh","year":"2011","unstructured":"Kurajoh M, Inaba M, Okuno S, Nagayama H, Yamada S, Imanishi Y, Ishimura E, Shoji S, Yamakawa T, Nishizawa Y (2011) Reduction of whole PTH\/intact PTH ratio as a predictor of bone metabolism in cinacalcet treatment of hemodialysis patients with secondary hyperparathyroidism. Osteoporos Int 22:923\u2013930","journal-title":"Osteoporos Int"},{"key":"690_CR21","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1046\/j.1523-1755.2001.00949.x","volume":"60","author":"MC Monier-Faugere","year":"2001","unstructured":"Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P, Cantor TL, Malluche HH (2001) Improved assessment of bone turnover by the PTH-(1\u201384)\/large C-PTH fragments ratio in ESRD patients. Kidney Int 60:1460\u20131468","journal-title":"Kidney Int"},{"key":"690_CR22","first-page":"59","volume":"1","author":"M Tanaka","year":"2008","unstructured":"Tanaka M, Komaba H, Itoh K, Matsushita K, Hamada Y, Fujii H, Fukagawa M (2008) The whole-PTH\/intact-PTH ratio is a useful predictor of severity of secondary hyperparathyroidism. NDT Plus 1:59\u201362","journal-title":"NDT Plus"},{"key":"690_CR23","first-page":"54","volume":"1","author":"H Komaba","year":"2008","unstructured":"Komaba H, Takeda Y, Shin J, Tanaka R, Kakuta T, Tominaga Y, Fukagawa M (2008) Reversed whole PTH\/intact PTH ratio as an indicator of marked parathyroid enlargement: five case studies and a literature review. NDT Plus 1:54\u201358","journal-title":"NDT Plus"},{"key":"690_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.bbrc.2009.02.023","volume":"381","author":"K Nakajima","year":"2009","unstructured":"Nakajima K, Nohtomi K, Sato M, Takano K, Sato K (2009) PTH(7\u201384) inhibits PTH(1\u201334)-induced 1,25-(OH)2D3 production in murine renal tubules. Biochem Biophys Res Commun 381:283\u2013287","journal-title":"Biochem Biophys Res Commun"},{"key":"690_CR25","doi-asserted-by":"publisher","first-page":"29821","DOI":"10.1074\/jbc.M705495200","volume":"282","author":"W Yuan","year":"2007","unstructured":"Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z, Li YC (2007) 1,25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 282:29821\u201329830","journal-title":"J Biol Chem"},{"key":"690_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.02101205","volume":"1","author":"S Schwarz","year":"2006","unstructured":"Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP (2006) Association of disorders in mineral metabolism with progression of chronic kidney disease. Clin J Am Soc Nephrol 1:825\u2013831","journal-title":"Clin J Am Soc Nephrol"},{"key":"690_CR27","doi-asserted-by":"publisher","first-page":"F1252","DOI":"10.1152\/ajprenal.00294.2011","volume":"302","author":"H Sugiura","year":"2012","unstructured":"Sugiura H, Yoshida T, Shiohira S, Kohei J, Mitobe M, Kurosu H, Kuro-o M, Nitta K, Tsuchiya K (2012) Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. Am J Physiol Renal Physiol 302:F1252\u2013F1264","journal-title":"Am J Physiol Renal Physiol"},{"key":"690_CR28","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1681\/ASN.2009080872","volume":"21","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Kong J, Deb DK, Chang A, Li YC (2010) Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 21:966\u2013973","journal-title":"J Am Soc Nephrol"},{"key":"690_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000437215","volume":"5","author":"Y Kaku","year":"2015","unstructured":"Kaku Y, Ookawara S, Miyazawa H, Ito K, Ueda Y, Hirai K, Hoshino T, Mori H, Yoshida I, Morishita Y, Tabei K (2015) Approximation of corrected calcium concentrations in advanced chronic kidney disease patients with or without dialysis therapy. Nephron Extra 5:39\u201349","journal-title":"Nephron Extra"},{"key":"690_CR30","doi-asserted-by":"publisher","first-page":"4744","DOI":"10.1210\/jc.2013-2139","volume":"98","author":"M Tepel","year":"2013","unstructured":"Tepel M, Armbruster FP, Gr\u00f6n HJ, Scholze A, Reichetzeder C, Roth HJ, Hocher B (2013) Nonoxidized, biologically active parathyroid hormone determines mortality in hemodialysis patients. J Clin Endocrinol Metab 98:4744\u20134751","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00690-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40620-019-00690-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-019-00690-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:56:34Z","timestamp":1777564594000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/33\/4\/795\/8328484"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1007\/s40620-019-00690-3","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"18 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was partly supported by Roche Diagnostics K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}